Sign in
PPCB Stock Price, Chart, Stats & News
Propanc Biopharma, Inc.
Save
Propanc Biopharma, Inc. (PPCB) does not currently pay a dividend.
1.44M
Market cap
–
Current P/E
–
Forward P/E
PPCB chart
Fundamentals
Gross margin | 0.44% |
Operating margin | -217705.14% |
Pretax margin | -220932.29% |
Net margin | -220932.29% |
Effective tax rate | – |
ROA | -437.20% |
ROE | -465.17% |
D/E | 0.16x |
Interest coverage ratio | -90.02x |
PPCB valuation
P/E | – |
P/S | 54.73x |
P/B | 0.13x |
P/CF | -0.44x |
P/FCF | -0.53x |
P/OCF | -0.44x |
PEG | -0.00x |
EV multiple | -0.01x |
About
Propanc Biopharma, Inc. (PPCB) is an Australian biopharmaceutical firm dedicated to developing innovative treatments for various cancers, with a particular focus on pancreatic, ovarian, and colorectal malignancies. The company's leading therapeutic candidate, PRP, is a unique formulation currently in the preclinical stage of development. This product is designed to enhance the effectiveness of multiple enzymes that work together to combat cancer.
Similar securities
Based on sector and market capitalization
Report issue